9,631 Shares in Catalent, Inc. (NYSE:CTLT) Acquired by Legacy Capital Group California Inc.

Legacy Capital Group California Inc. purchased a new stake in Catalent, Inc. (NYSE:CTLT - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 9,631 shares of the company's stock, valued at approximately $583,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Sound Income Strategies LLC raised its position in Catalent by 4,466.7% in the 1st quarter. Sound Income Strategies LLC now owns 1,370 shares of the company's stock valued at $77,000 after buying an additional 1,340 shares during the last quarter. Norden Group LLC bought a new stake in shares of Catalent in the first quarter worth $1,222,000. Principal Financial Group Inc. lifted its position in shares of Catalent by 1.7% in the first quarter. Principal Financial Group Inc. now owns 206,694 shares of the company's stock worth $11,668,000 after purchasing an additional 3,499 shares in the last quarter. Commonwealth Equity Services LLC acquired a new position in Catalent during the first quarter worth $1,736,000. Finally, Diversify Advisory Services LLC bought a new position in Catalent in the first quarter valued at $1,040,000.

Catalent Stock Performance

Shares of CTLT traded down $0.41 during mid-day trading on Friday, reaching $59.09. The company's stock had a trading volume of 2,466,800 shares, compared to its average volume of 2,052,115. The company has a current ratio of 2.52, a quick ratio of 1.96 and a debt-to-equity ratio of 1.35. Catalent, Inc. has a 1-year low of $31.80 and a 1-year high of $61.20. The business has a 50-day simple moving average of $60.12 and a two-hundred day simple moving average of $57.88. The stock has a market cap of $10.69 billion, a P/E ratio of -9.69, a PEG ratio of 2.14 and a beta of 1.15.

Catalent (NYSE:CTLT - Get Free Report) last posted its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share for the quarter, beating analysts' consensus estimates of $0.44 by $0.13. Catalent had a negative return on equity of 0.56% and a negative net margin of 22.72%. The business had revenue of $1.30 billion for the quarter, compared to analysts' expectations of $1.23 billion. As a group, equities research analysts anticipate that Catalent, Inc. will post 0.95 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Alessandro Maselli sold 9,088 shares of Catalent stock in a transaction dated Monday, July 29th. The shares were sold at an average price of $58.76, for a total transaction of $534,010.88. Following the completion of the sale, the chief executive officer now owns 177,521 shares of the company's stock, valued at approximately $10,431,133.96. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Catalent news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares in the company, valued at $10,431,133.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ricky Hopson sold 662 shares of the firm's stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares in the company, valued at approximately $1,785,251.44. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 12,730 shares of company stock valued at $751,870 over the last ninety days. 0.31% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on CTLT. Barclays increased their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an "equal weight" rating in a research note on Friday, June 28th. Baird R W cut Catalent from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, September 24th. William Blair restated a "market perform" rating on shares of Catalent in a research note on Tuesday, September 3rd. StockNews.com initiated coverage on Catalent in a research note on Saturday, October 12th. They set a "hold" rating on the stock. Finally, Robert W. Baird reissued a "neutral" rating and issued a $63.50 price objective on shares of Catalent in a report on Tuesday, September 24th. Nine equities research analysts have rated the stock with a hold rating, Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $59.83.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.